concentraat voor oplossing voor infusie clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)
This study looks at two different ways to treat pancreatic cancer that can or might be surgically removed. It compares using a specific combination of powerful medicines before surgery to another powerful medicine combined with radiation before surgery, followed by more medicine. The main goal is to see which treatment helps people live longer.
For: non-metastatic (borderline) resectable pancreatic cancerNetherlands - AuthorisedTherapeutic exploratory (Phase II)
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)
This study looks at new ways to treat bowel cancer that has spread to the lining of the tummy. It tests a combination of medicines given before surgery to see if it helps patients. The goal is to improve treatment for this type of cancer.
For: Patients with colorectal peritoneal metastases with a PCI-score of 1-20Netherlands - AuthorisedTherapeutic use (Phase IV)
Lantiolihaspuudutuksen vaikutus munuaisen poistoleikkauksen jälkeiseen kivun hoitoon ja toipumiseen
This study is looking at different ways to help with pain after kidney cancer surgery. It's testing if a nerve block, using medicines like ropivacaine and dexamethasone, can reduce the amount of strong pain medicine (opiates) people need within the first 24 hours after their operation. It also checks how long it takes for a person to ask for pain relief.
For: Renal cancerFinland - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)
This study is looking at a new way to treat an advanced form of lung cancer. It combines a special vaccine made from your own cells with an existing cancer medicine to see if it helps reduce side effects and works better.
For: metastatic non-small-cell lung cancerBelgium